✦ LIBER ✦

One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet’s disease refractory to standard immunosuppressive drugs

✍ Scribed by AnnaRita Giardina; Angelo Ferrante; Francesco Ciccia; Maria Vadalà; Ennio Giardina; Giovanni Triolo

Publisher: Springer
Year: 2009
Tongue: English
Weight: 249 KB
Volume: 31
Category: Article
ISSN: 0172-8172
DOI: 10.1007/s00296-009-1213-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of infliximab in the treatment

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in behçet's disease: An open-label trial

✍ Ilknur Tugal-Tutkun; Abdulbaki Mudun; Meri Urgancioglu; Sevil Kamali; Esen Kasap 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 2 views

Potential of Preventive Treatment of Alz

Potential of Preventive Treatment of Alzheimer’s Disease: Results of a Three-Year Prospective Open Comparative Trial of the Efficacy and Safety of Courses of Treatment with Cerebrolysin and Cavinton in Elderly Patients with Mild Cognitive Impairment Syndrome

✍ S. I. Gavrilova; I. V. Kolykhalov; Ya. B. Fedorova; N. D. Selezneva; Ya. B. Kaly 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 244 KB

A six-month multicentre, double-blind, b

A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled byl-dopa

✍ E. R. Brunt; D. J. Brooks; A. D. Korczyn; J.-L. Montastruc; F. Stocchi; on behal 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 79 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre